Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus

Sang Youl Rhee; Young Seol Kim; Suk Chon; Seungjoon Oh; Jeong-Taek Woo; Sung Woon Kim; Jin-Woo Kim

doi:10.1016/j.diabres.2010.09.009

Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus

Diabetes Res Clin Pract. 2011 Jan;91(1):e11-4. doi: 10.1016/j.diabres.2010.09.009. Epub 2010 Oct 8.

Authors

Sang Youl Rhee¹, Young Seol Kim, Suk Chon, Seungjoon Oh, Jeong-Taek Woo, Sung Woon Kim, Jin-Woo Kim

Affiliation

¹ Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Republic of Korea.

PMID: 20934769
DOI: 10.1016/j.diabres.2010.09.009

Abstract

We analyzed the medical records of 884 type 2 DM patients who were taking different antiplatelet agents for more than 2 years. Based on the records, occurrences of cardiovascular events for 10 years were evaluated. The composite disease-free survival rate for cilostazol monotherapy group was similar to aspirin subgroup (p=0.133).

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aspirin / therapeutic use
Cardiovascular Diseases / epidemiology
Cardiovascular Diseases / prevention & control
Cerebrovascular Disorders / epidemiology
Cerebrovascular Disorders / prevention & control
Cilostazol
Diabetes Mellitus, Type 2 / complications*
Diabetes Mellitus, Type 2 / drug therapy*
Diabetic Angiopathies / epidemiology
Diabetic Angiopathies / prevention & control*
Disease-Free Survival
Drug Therapy, Combination
Female
Humans
Male
Medical Records
Middle Aged
Peripheral Arterial Disease / epidemiology
Peripheral Arterial Disease / prevention & control
Platelet Aggregation Inhibitors / therapeutic use*
Proportional Hazards Models
Republic of Korea / epidemiology
Retrospective Studies
Tetrazoles / therapeutic use*

Substances

Platelet Aggregation Inhibitors
Tetrazoles
Cilostazol
Aspirin